ICH Q13

This guideline is intended for pharmaceutical manufacturers who use continuous manufacturing processes or who wish to transition from traditional batch manufacturing to continuous processes—from active pharmaceutical ingredient (API) manufacturing to the production of solid dosage forms. It is particularly relevant for manufacturers who are planning new facilities or wish to convert existing approvals to continuous processes.

• Control Strategy: The totality of measures taken to ensure product quality during the ongoing process

• Process Dynamics: Understanding and controlling material residence time, mixing, and traceability in a continuous flow

• Batch definition: A scientifically based determination of what constitutes a “batch” in a continuous process

• Real-Time Release Testing (RTRT): The ability to verify product quality through continuous process monitoring rather than solely through final product testing

• Handling of Nonconforming Material: Defined procedures for handling material during process disturbances or startup/shutdown operations

• Link to ICH Q8–Q10: Integration into the established principles of product development, risk management, and quality systems

ICH Q10 generally describes a pharmaceutical quality system covering the entire product life cycle, regardless of whether a manufacturer uses traditional batch manufacturing or continuous processes. ICH Q13 builds on these fundamental principles but addresses the specific challenges of continuous manufacturing in much greater detail—such as how a batch is defined when there is no clear start and end point, or how process deviations are handled in a continuous material flow. ICH Q10 thus provides the framework, while ICH Q13 outlines the process-specific guidelines for continuous manufacturing.

An inadequately justified control strategy or batch definition can lead regulatory authorities to reject an application for approval of a continuous manufacturing process or to request additional data—resulting in corresponding delays in market launch. For processes that have already been approved, gaps in process dynamics monitoring during inspections can lead to findings of nonconformities, since continuous processes without robust real-time monitoring carry a higher risk of undetected quality deviations than traditional batch manufacturing.

• ICH Q10 – Pharmaceutical Quality System

• EU GMP – European Guidelines on Good Manufacturing Practice

• FDA cGMP – U.S. Requirements for Drug Manufacturing

• ALCOA+ – Fundamental Principles of Data Integrity